A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza
Open Access
- 22 December 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigenviathe cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105in vitro. To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccineviaa simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen.Keywords
This publication has 69 references indexed in Scilit:
- Comparison of Internal Ribosome Entry Site (IRES) and Furin-2A (F2A) for Monoclonal Antibody Expression Level and Quality in CHO CellsPLOS ONE, 2013
- Antibody-based protection against HIV infection by vectored immunoprophylaxisNature, 2011
- Anti-CD180 (RP105) Activates B Cells To Rapidly Produce Polyclonal Ig via a T Cell and MyD88-Independent PathwayThe Journal of Immunology, 2011
- Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B CellsThe Journal of Immunology, 2011
- S1P1 receptor directs the release of immature B cells from bone marrow into bloodJournal of Experimental Medicine, 2010
- Advances in DNA immunization against hepatitis C virus infection: Opportunities and challengesHuman Vaccines, 2009
- Loss of hepatic B cells following lipopolysaccharide injection and polymicrobial sepsisJournal of Gastroenterology and Hepatology, 2009
- Influenza PR8 HA-specific Fab fragments produced by phage display methodsBiochemical and Biophysical Research Communications, 2008
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005
- What is trogocytosis and what is its purpose?Nature Immunology, 2003